Inflammatory Spleen Monocytes Can Upregulate CD11c Expression Without Converting into Dendritic Cells

Monocytes can differentiate into various cell types with unique specializations depending on their environment. Under certain inflammatory conditions, monocytes upregulate expression of the dendritic cell marker CD11c together with MHC and costimulatory molecules. These phenotypic changes indicate monocyte differentiation into a specialized subset of dendritic cells (DCs), often referred to as monocyte-derived DCs or inflammatory DCs (iDCs), considered important mediators of immune responses under inflammatory conditions triggered by infection or vaccination. To characterize the relative contribution of cDCs and iDCs under conditions that induce strong immunity to coadministered Ags, we analyzed the behavior of spleen monocytes in response to anti-CD40 treatment. We found that under sterile inflammation in mice triggered by CD40 ligation, spleen monocytes can rapidly and uniformly exhibit signs of activation, including a surface phenotype typically associated with their conversion into DCs. These inflammatory monocytes remain closely related to their monocytic lineage, preserving expression of CD115, scavenging function, tissue distribution and poor capacity for Ag presentation characteristic of their monocyte precursors. In addition, 3–4 d after delivery of the inflammatory stimuli, these cells reverted to a monocyte-associated phenotype typical of the steady state. These findings indicate that, in response to anti-CD40 treatment, spleen monocytes are activated and express certain DC surface markers without acquiring functional characteristics associated with DCs.

[1]  M. Bevan,et al.  Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection , 2011, Nature.

[2]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[3]  R. Steinman,et al.  Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A , 2011, Proceedings of the National Academy of Sciences.

[4]  F. Sallusto,et al.  Monocytes Join the Dendritic Cell Family , 2010, Cell.

[5]  R. Steinman,et al.  Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas , 2010, Cell.

[6]  E. Trombetta,et al.  Dendritic Cells Continue To Capture and Present Antigens after Maturation In Vivo , 2010, The Journal of Immunology.

[7]  Nina Bhardwaj,et al.  CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells , 2010, PloS one.

[8]  H. Hammad,et al.  The lung vascular filter as a site of immune induction for T cell responses to large embolic antigen , 2009, The Journal of experimental medicine.

[9]  A. Rudensky,et al.  In Vivo Analysis of Dendritic Cell Development and Homeostasis , 2009, Science.

[10]  F. Geissmann,et al.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.

[11]  M. Merad,et al.  MHC Class I/Peptide Transfer between Dendritic Cells Overcomes Poor Cross-Presentation by Monocyte-Derived APCs That Engulf Dying Cells1 , 2009, The Journal of Immunology.

[12]  M. Jenkins,et al.  Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. , 2009, Immunity.

[13]  David A. Hume,et al.  Macrophages as APC and the Dendritic Cell Myth , 2008, The Journal of Immunology.

[14]  F. Tacke,et al.  CCR2 Mediates Homeostatic and Inflammatory Release of Gr1high Monocytes from the Bone Marrow, but Is Dispensable for Bladder Infiltration in Bacterial Urinary Tract Infection1 , 2008, The Journal of Immunology.

[15]  R. Steinman Dendritic cells in vivo: a key target for a new vaccine science. , 2008, Immunity.

[16]  María López-Bravo,et al.  Review in Vivo Induction of Immune Responses to Pathogens by Conventional Dendritic Cells , 2022 .

[17]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[18]  B. León,et al.  Monocyte‐derived dendritic cells in innate and adaptive immunity , 2008, Immunology and cell biology.

[19]  T. Hohl,et al.  Monocyte-mediated defense against microbial pathogens. , 2008, Annual review of immunology.

[20]  G. Randolph,et al.  Antigen presentation by monocytes and monocyte-derived cells. , 2008, Current opinion in immunology.

[21]  M. Colonna,et al.  Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells , 2007, The Journal of experimental medicine.

[22]  Steffen Jung,et al.  Monocytes give rise to mucosal, but not splenic, conventional dendritic cells , 2007, The Journal of experimental medicine.

[23]  R. Steinman,et al.  Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin1 , 2006, The Journal of Immunology.

[24]  Kenneth D. Gibbs,et al.  Dendritic Cells Cross-Dressed with Peptide MHC Class I Complexes Prime CD8+ T Cells1 , 2006, The Journal of Immunology.

[25]  Family , 2006 .

[26]  F. Tacke,et al.  Migratory fate and differentiation of blood monocyte subsets. , 2006, Immunobiology.

[27]  J. Yewdell,et al.  CD8αα-Mediated Intraepithelial Lymphocyte Snatching of Thymic Leukemia MHC Class Ib Molecules In Vitro and In Vivo1 , 2006, The Journal of Immunology.

[28]  Li Wu,et al.  Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes , 2006, Nature Immunology.

[29]  F. Ginhoux,et al.  Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery , 2006, The Journal of experimental medicine.

[30]  Kenneth D. Gibbs,et al.  Tumor-Specific CD4+ T Cells Are Activated by “Cross-Dressed” Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines1 , 2006, The Journal of Immunology.

[31]  J. Yewdell,et al.  CD8 alpha alpha-mediated intraepithelial lymphocyte snatching of thymic leukemia MHC class Ib molecules in vitro and in vivo. , 2006, Journal of immunology.

[32]  Simon C Watkins,et al.  IL-18–induced CD83+CCR7+ NK helper cells , 2005, The Journal of experimental medicine.

[33]  T. Rowley,et al.  Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs1 , 2004, The Journal of Immunology.

[34]  R. Offringa,et al.  Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.

[35]  R. Fairchild,et al.  CD40 Engagement Enhances Antigen-Presenting Langerhans Cell Priming of IFN-γ-Producing CD4+ and CD8+ T Cells Independently of IL-121 , 2004, The Journal of Immunology.

[36]  R. Steinman,et al.  The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.

[37]  N. Van Rooijen,et al.  Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.

[38]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[39]  Clare L. Bennett,et al.  Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo , 2003, The Journal of experimental medicine.

[40]  I. Mellman,et al.  Presentation of Exogenous Antigens on Major Histocompatibility Complex (MHC) Class I and MHC Class II Molecules Is Differentially Regulated during Dendritic Cell Maturation , 2003, The Journal of experimental medicine.

[41]  E. Pamer,et al.  TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. , 2003, Immunity.

[42]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[43]  R. Steinman,et al.  Immune Tolerance After Delivery of Dying Cells to Dendritic Cells In Situ , 2002, The Journal of experimental medicine.

[44]  J. Gribben,et al.  CD40 ligand therapy of lymphoma patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[46]  J. Gribben,et al.  Phase I study of recombinant human CD40 ligand in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Sally R. M. Clarke,et al.  The critical role of CD40/CD40L in the CD4‐dependent generation of CD8+ T cell immunity , 2000, Journal of leukocyte biology.

[48]  J. Altman,et al.  Soluble Antigen and CD40 Triggering Are Sufficient to Induce Primary and Memory Cytotoxic T Cells1 , 2000, The Journal of Immunology.

[49]  R. Steinman,et al.  Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. , 1999, Immunity.

[50]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[51]  D. Longo,et al.  Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3) , 1994, Journal of immunology.